Stryker Completes Acquisition of Amplitude Vascular Systems

Why It Matters

The acquisition equips Stryker with a proprietary IVL solution, enabling it to capture rising demand for calcified‑artery therapies and to compete directly with rivals that are investing billions in the same technology space.

Key Takeaways

• Stryker adds Pulse IVL platform to peripheral vascular lineup
• IVL market sees $30+ billion in recent medtech acquisitions
• Johnson & Johnson’s Shockwave deal tops 2024 medtech M&A
• Stryker signals more M&A activity through 2025

Pulse Analysis

Intravascular lithotripsy (IVL) has emerged as a breakthrough for treating heavily calcified arterial lesions that traditional balloon angioplasty cannot safely address. By delivering controlled pressure waves through a CO₂‑inflated balloon, the technology fractures calcium while preserving surrounding tissue, improving vessel compliance and reducing procedural complications. Clinicians increasingly view IVL as a versatile tool for both peripheral artery disease and complex coronary interventions, driving a surge in clinical trials and regulatory approvals worldwide.

The competitive landscape for IVL is now defined by a series of high‑profile acquisitions. Johnson & Johnson’s $13.1 billion purchase of Shockwave Medical set a new benchmark for med‑tech M&A in 2024, while Boston Scientific and Abbott have each spent hundreds of millions to secure Bolt Medical and Cardiovascular Systems, respectively. These deals reflect a strategic push to own end‑to‑end solutions for calcified disease, a segment projected to grow double‑digit percentages as the aging population presents more complex vascular cases. Stryker’s entry with Amplitude’s Pulse platform adds another heavyweight to the fray, expanding its peripheral vascular suite beyond the Inari clot‑removal assets.

For investors, Stryker’s rapid execution signals confidence in its cash position and a willingness to use M&A to accelerate growth. The IVL addition not only diversifies revenue streams but also positions the company to benefit from upcoming reimbursement reforms that favor minimally invasive, high‑value therapies. As the market consolidates, firms that can integrate IVL with existing product lines and demonstrate robust clinical outcomes are likely to capture a larger share of the projected multi‑billion‑dollar IVL opportunity. Stryker’s leadership has hinted at further deals through 2025, suggesting the acquisition of Amplitude is just the first step in a broader expansion strategy.

Deal Summary

Stryker has completed its acquisition of Amplitude Vascular Systems, the developer of the Pulse intravascular lithotripsy platform for treating severely calcified arterial disease. Financial terms were not disclosed. The deal expands Stryker's peripheral vascular portfolio with IVL technology.